Acadia Healthcare Company Inc (NASDAQ:ACHC)‘s stock had its “hold” rating restated by equities researchers at Cantor Fitzgerald in a report released on Friday. They currently have a $45.00 target price on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 2.18% from the stock’s current price.
The analysts wrote, “Last night’s commitment to an additional $15 billion of federal spending for mental health and addiction spending amounts to three times the current federal mental health block grant, and represents a major boost in federal.””
Several other research analysts have also weighed in on ACHC. Jefferies Group LLC restated a “buy” rating on shares of Acadia Healthcare Company in a research note on Friday, December 2nd. TheStreet lowered shares of Acadia Healthcare Company from a “hold” rating to a “sell” rating in a research note on Friday, December 2nd. Zacks Investment Research upgraded shares of Acadia Healthcare Company from a “sell” rating to a “hold” rating in a research note on Tuesday, December 20th. Royal Bank of Canada restated a “buy” rating and set a $56.00 price objective on shares of Acadia Healthcare Company in a research note on Tuesday, January 3rd. Finally, Citigroup Inc initiated coverage on shares of Acadia Healthcare Company in a research note on Wednesday, January 4th. They set a “buy” rating and a $43.00 price objective on the stock. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $59.55.
Acadia Healthcare Company (NASDAQ:ACHC) opened at 44.04 on Friday. Acadia Healthcare Company has a 52 week low of $32.54 and a 52 week high of $65.00. The firm’s 50-day moving average is $42.03 and its 200-day moving average is $40.84. The company has a market cap of $3.86 billion, a PE ratio of 629.14 and a beta of 0.91.
Acadia Healthcare Company (NASDAQ:ACHC) last released its quarterly earnings data on Thursday, February 23rd. The company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. The company had revenue of $702.89 million for the quarter, compared to analyst estimates of $708.41 million. Acadia Healthcare Company had a net margin of 0.22% and a return on equity of 8.91%. Acadia Healthcare Company’s revenue for the quarter was up 41.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.59 EPS. On average, analysts expect that Acadia Healthcare Company will post $2.46 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Mideast Time and is owned by of Mideast Time. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.mideasttime.com/acadia-healthcare-company-inc-achc-rating-reiterated-by-cantor-fitzgerald/1589940.html.
In related news, VP Randall P. Goldberg sold 914 shares of the company’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $43.55, for a total value of $39,804.70. Following the transaction, the vice president now owns 7,376 shares in the company, valued at approximately $321,224.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 17.20% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ACHC. Price T Rowe Associates Inc. MD raised its position in shares of Acadia Healthcare Company by 11.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 10,958,149 shares of the company’s stock worth $542,976,000 after buying an additional 1,103,621 shares during the period. Wells Fargo & Company MN raised its position in shares of Acadia Healthcare Company by 30.0% in the third quarter. Wells Fargo & Company MN now owns 6,857,782 shares of the company’s stock worth $339,803,000 after buying an additional 1,581,959 shares during the period. JPMorgan Chase & Co. raised its position in shares of Acadia Healthcare Company by 20.2% in the third quarter. JPMorgan Chase & Co. now owns 6,008,192 shares of the company’s stock worth $297,706,000 after buying an additional 1,008,466 shares during the period. TCW Group Inc. raised its position in shares of Acadia Healthcare Company by 11.9% in the fourth quarter. TCW Group Inc. now owns 2,251,809 shares of the company’s stock worth $74,535,000 after buying an additional 238,755 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of Acadia Healthcare Company by 3.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,888,720 shares of the company’s stock worth $93,586,000 after buying an additional 64,549 shares during the period.
About Acadia Healthcare Company
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Receive News & Ratings for Acadia Healthcare Company Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Company Inc and related companies with MarketBeat.com's FREE daily email newsletter.